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Abstract
Background: From 1968 to 2002, Singapore experienced an almost four-fold increase in prostate
cancer incidence. This paper examines the incidence, mortality and survival patterns for prostate
cancer among all residents in Singapore from 1968 to 2002.
Methods: This is a retrospective population-based cohort study including all prostate cancer cases
aged over 20 (n = 3613) reported to the Singapore Cancer Registry from 1968 to 2002. Age-
standardized incidence, mortality rates and 5-year Relative Survival Ratios (RSRs) were obtained
for each 5-year period. Follow-up was ascertained by matching with the National Death Register
until 2002. A weighted linear regression was performed on the log-transformed age-standardized
incidence and mortality rates over period.
Results: The percentage increase in the age-standardized incidence rate per year was 5.0%, 5.6%,
4.0% and 1.9% for all residents, Chinese, Malays and Indians respectively. The percentage increase
in age-standardized mortality rate per year was 5.7%, 6.0%, 6.6% and 2.5% for all residents, Chinese,
Malays and Indians respectively. When all Singapore residents were considered, the RSRs for
prostate cancer were fairly constant across the study period with slight improvement from 1995
onwards among the Chinese.
Conclusion: Ethnic differences in prostate cancer incidence, mortality and survival patterns were
observed. There has been a substantial improvement in RSRs since the 1990s for the Chinese.
Background
Prostate cancer is now the fifth most common cancer
among Singaporean males, with a world age-standardized
incidence rate (ASR) of 17.4 per 100,000 from 1998–
2002 [1]. The average annual rate of increase between
1968 and 2002 was 5.6%, with a steeper increase seen in
the last 10 years. Signorello and Adami noted that Asian
countries have a lower prostate cancer incidence than
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Western countries [2]. From the Global Estimates of Can-
cer (GLOBOCAN) 2002, the incidence rate of prostate
cancer in Singapore (ASR of 13.7 per 100,000) was much
lower than that of Western countries such as the United
States (ASR of 118.4 per 100,000), but high compared to
other Asian countries such as China (ASR of 1.7 per
100,000) and India (ASR of 4.6 per 100,000) [3].
Interestingly, in spite of the increasing incidence of pros-
tate cancer in many countries, significant reduction in
prostate cancer mortality has been reported in the United
Kingdom, United States, Austria, Canada, Italy, France,
Germany, Australia and Spain [4]. One of the controver-
sial possible reasons that has been proposed for the reduc-
tion in prostate cancer mortality is the widespread use of
prostate-specific antigen (PSA) screening in some of the
developed countries, especially in the United States. How-
ever, PSA screening is not routinely done in Singapore, so
the time trends in prostate cancer incidence and mortality
rates, and a comparison of mortality rates with other
developed countries could reveal relationships between
incidence and mortality in the absence of the confound-
ing effect of PSA screening. To better elucidate the progress
against cancer treatment, Dickman and Adami proposed
the simultaneous interpretation of trends in incidence,
mortality and survival [5]. Therefore, in this paper, we
investigated the relationship between prostate cancer inci-
dence, mortality and 5-year relative survival from 1968 to
2002 in all Singapore males and in the Chinese sub-pop-
ulation, to explore plausible explanations for any trends
observed.
Methods
Study Population
This is a retrospective population-based cohort study
using data from the Singapore Cancer Registry which was
established in 1968. All medical practitioners and pathol-
ogy laboratories voluntarily notify the registry of any inci-
dent cancers, and registry staff also validate hospital
discharges and death certificates against registered cases to
ensure completeness.
Prostate cancer cases aged 20 and above (n = 3613) were
identified. 78.4% of these cases were Chinese, 10.5%
Malay, 7.8% Indian and 3.3% "Others". The median age
of diagnosis was 73 and the interquartile range was 66 to
79. A small number of cases (n = 120) ascertained from
Death Certificate Only (DCO) or diagnosed with other
forms of cancers were excluded in the relative survival
analysis, leaving a total of 3493 cases.
The Registration of Births and Deaths Act in Singapore
requires death to be reported within three days [6]. The
Electoral Register in 1996 was used to verify the vital sta-
tus of Singapore residents in this study. 115 cancer cases
diagnosed prior to 1997, but not matched to the electoral
register in 1996 or to the death register, were censored at
2005. Since the emigration rates in Singapore are gener-
ally low, emigration of prostate cancer cases is unlikely to
affect the study's findings [7].
Statistical analysis
The prostate cancer incidence and (cause-specific) mortal-
ity rates were age-standardized using the world standard
population with 5-year age groups (20–24, 25–30, ..., 75–
79, 80+) and calendar periods (1968–1972, ..., 1998–
2002). The denominators for both incidence and mortal-
ity rates were the total number of person-years from the
Singapore resident population based on the Singapore
Population Census reports. The confidence intervals for
the ASRs were computed using the gamma distribution
approach [8]. To test for any linear trend over time in the
log-transformed ASRs, we performed a weighted linear
regression with the inverse of the variance as weight, and
performed a Wald test. We used the coefficient of determi-
nation (R2) to assess the goodness-of-fit of the regression
model.
Relative survival was used to measure the survival of pros-
tate cancer patients. This is the ratio of the observed sur-
vival of patients to the expected survival of a comparable
group in the general population. The expected survival
rates, which were estimated from all causes of death in the
general Singapore population, were computed using the
Ederer II method [9]. A period-based approach was
adopted to give a more up-to-date estimate on cancer sur-
vival [10,11]. Age-standardization of the RSRs to the
World Standard Cancer Population [12] was performed
using Brenner's approach [10], with age being categorized
into four groups (20–54, 55–64, 65–74, 75+ years) for all
prostate cancer cases and three groups (20–64, 65–74,
75+ years) for prostate cancer sub-groups.
Results
From 1968 to 2002, the ASRs of prostate cancer (per
100,000) were 18.7 (95% CI: 18.1–19.3) for all Singapore
residents, 18.7 (95% CI: 18.0–19.4) for Chinese, 18.1
(95% CI: 16.2–20.0) for Malays and 15.3 (95% CI: 13.5–
17.3) for Indians. In the most recent period of 1998 to
2002, the ASRs (per 100,000) were 29.2 (95% CI: 27.6–
30.8) for all Singapore residents, 30.9 (95% CI: 29.1–
32.8) for Chinese, 26.8 (95% CI: 22.4–31.8) for Malays
and 18.6 (95% CI: 14.6–23.3) for Indians. The ASRs of
prostate cancer increased over the years, with a steeper gra-
dient since the 1990s, particularly for the Chinese and
Malays (Figure 1). The percentage increase in ASRs per
year from 1968 to 2002 was 5.0%, 5.6%, 4.0% and 1.9%
for all residents (p < 0.0005), Chinese (p < 0.0005),
Malays (p < 0.0005) and Indians (p = 0.079) respectively.
A linear regression model provided a good fit to the dataBMC Cancer 2008, 8:368 http://www.biomedcentral.com/1471-2407/8/368
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(R2 = 94–99%) for all residents, Chinese and Malays but
only a modest fit for Indians (R2 = 49%).
Although there was an increase in the age-standardized
mortality rates, it was less marked than the ASRs (Figure
1). The percentage increase in age-standardized mortality
rate per year from 1968 to 2002 was 5.7%, 6.0%, 6.6%
and 2.5% for all residents, Chinese, Malays and Indians
respectively, with significant percentage increase for all
residents (p < 0.0005), Chinese (p < 0.0005) and Malays
(p = 0.003), but not for Indians (p = 0.157). A linear
regression model provided a good fit to the data (R2 = 86–
99%) for all residents, Chinese and Malays but only a
modest fit for Indians (R2 = 36%). Across the study period,
The incidence (black circle), mortality (dark gray square) and 5-year relative survival (light gray diamond) rates for all prostate  cancer cases in (a) Singapore residents, (b) Chinese, (c) Malays and (d) Indians Figure 1
The incidence (black circle), mortality (dark gray square) and 5-year relative survival (light gray diamond) 
rates for all prostate cancer cases in (a) Singapore residents, (b) Chinese, (c) Malays and (d) Indians. The vertical 
bars are the 95%CI for the different measures.
1970 1975 1980 1985 1990 1995 2000
0
5
1
0
1
5
2
0
2
5
3
0
a) All
year
A
S
R
 
p
e
r
 
1
0
0
,
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
5
-
y
e
a
r
 
R
S
R
s
 
(
%
)
Incidence
Mortality
5-year RSRs
1970 1975 1980 1985 1990 1995 2000
0
5
1
0
1
5
2
0
2
5
3
0
b) Chinese
year
A
S
R
 
p
e
r
 
1
0
0
,
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
5
-
y
e
a
r
 
R
S
R
s
 
(
%
)
1970 1975 1980 1985 1990 1995 2000
0
5
1
0
1
5
2
0
2
5
3
0
c) Malays
year
A
S
R
 
p
e
r
 
1
0
0
,
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
5
-
y
e
a
r
 
R
S
R
s
 
(
%
)
1970 1975 1980 1985 1990 1995 2000
0
5
1
0
1
5
2
0
2
5
3
0
d) Indians
year
A
S
R
 
p
e
r
 
1
0
0
,
0
0
0
0
2
0
4
0
6
0
8
0
1
0
0
1
2
0
5
-
y
e
a
r
 
R
S
R
s
 
(
%
)BMC Cancer 2008, 8:368 http://www.biomedcentral.com/1471-2407/8/368
Page 4 of 6
(page number not for citation purposes)
the age-standardized mortality rates among Indians were
generally lower than the Chinese and Malays in the late
1980s (Table 1).
When all Singapore residents were considered, the relative
survival rates for prostate cancer were fairly constant
across the study period with slight improvement from
1995 onwards among the Chinese (Figure 1a, b). It is dif-
ficult to interpret the RSRs for Malays and Indians given
the small number of cases and large confidence intervals
(Figure 1c and 1d).
Discussion
There have been few reports on prostate cancer in differ-
ent ethnic groups in Asian countries. With access to high
quality data, we conducted this study to gain insights into
the epidemiology of prostate cancer in an Asian popula-
tion. Our analysis showed that the incidence and mortal-
ity rates of prostate cancer have been on the rise in
Singapore over the last few decades and more rapidly
since the 1990s. For all residents (Figure 1a), both the
incidence and mortality rates were increasing but diverg-
ing, especially after 1990. The temporal trends in prostate
cancer incidence and mortality rates, and RSRs were differ-
ent for the Chinese, Malays and Indians living in Singa-
pore (Figures 1b to 1d). The differences are not likely to be
explained by the differential access to health care by eth-
nicity as universal health coverage is provided to all Singa-
poreans regardless of their ability to pay [13]. However,
the three ethnic groups do differ with regards to lifestyle,
especially in the past. Though immigration rates in Singa-
pore have increased gradually over time, most immigrants
were from countries with similar cultures and lifestyles
[14]. Therefore, our results are not likely to be affected by
immigration trends.
Generally, prostate cancer incidence and mortality rates
are higher in Western countries than Asian countries. Our
study found that in Singapore during 1998 to 2002, the
highest and lowest ASRs per 100,000 were 30.9 (Chinese)
Table 1: Age adjusted incidence and mortality rates, and 5-year Relative Survival Ratio (RSR) of all prostate cancers from 1968 to 
2002, aged 20 and above for all residents, Chinese, Malays and Indians
Period Incidence Rate (per 100,000) Mortality Rate (per 100,000) Relative Survival Ratio (%)
Total Rate (95% CI) Total Rate (95% CI) N* Ratio (95% CI)
All 1968–1972 94 6.7 (5.3–8.4) 23 1.6 (0.9–2.4) - -
1973–1977 143 8.6 (7.1–10.2) 35 2.0 (1.4–2.9) 31.7 48.1 (34.6–62.5)
1978–1982 239 11.3 (9.8–12.9) 69 3.4 (2.6–4.3) 57.4 53.0 (43.4–62.8)
1983–1987 356 13.8 (12.4–15.4) 106 4.1 (3.3–5.0) 94.8 49.7 (41.7–57.8)
1988–1992 527 16.3 (14.9–17.7) 187 5.7 (4.9–6.6) 155.7 55.8 (49.1–62.6)
1993–1997 903 23.2 (21.7–24.8) 303 7.7 (6.9–8.7) 214.9 53.5 (48.1–59.0)
1998–2002 1351 29.2 (27.6–30.8) 434 9.3 (8.5–10.3) 394.5 60.9 (56.6–65.1)
Chinese 1968–1972 74 6.4 (4.9–8.2) 18 1.5 (0.8–2.5) - -
1973–1977 104 7.7 (6.2–9.4) 30 2.2 (1.4–3.2) 22.8 36.5 (23.3–51.5)
1978–1982 179 10.5 (9.0–12.2) 52 3.1 (2.3–4.1) 37.6 46.6 (35.9–57.8)
1983–1987 257 12.7 (11.2–14.4) 75 3.6 (2.8–4.6) 65.1 46.8 (37.6–56.5)
1988–1992 411 16.3 (14.7–17.9) 148 5.6 (4.7–6.6) 111.8 58.8 (50.9–66.6)
1993–1997 718 24.1 (22.3–25.9) 239 7.8 (6.8–8.8) 167.4 53.0 (46.8–59.2)
1998–2002 1091 30.9 (29.1–32.8) 342 9.6 (8.6–10.7) 306.4 61.7 (56.8–66.5)
Malays 1968–1972 9 7.2 (3.1–14.2) 2 1.2 (0.1–4.5)
1973–1977 19 11.4 (6.5–18.6) 2 0.9 (0.1–3.7) 3.7 78.1 (28.7–125.1)
1978–1982 25 11.6 (7.3–17.5) 7 2.9 (1–6.4) 8.4 69.1 (40.3–97.2)
1983–1987 45 15.5 (11.2–21.0) 13 4.5 (2.4–7.9) 14.7 51 (30.3–73)
1988–1992 54 14.9 (11.1–19.6) 22 6.4 (3.9–9.7) 19.6 26.3 (14.2–42)
1993–1997 90 21.3 (17.1–26.2) 41 10.4 (7.4–14.1) 16.0 35.9 (21.5–52.4)
1998–2002 137 26.8 (22.4–31.8) 51 10.0 (7.4–13.3) 30.5 64.1 (50–77.4)
Indians 1968–1972 7 4.9 (1.6–11.3) 2 1.7 (0.1–7.9)
1973–1977 16 11.6 (5.7–21.1) 3 2.0 (0.4–5.8) 1.0 31.7 (4.7–75.8)
1978–1982 26 15.3 (9.6–23.3) 5 3.1 (0.9–7.5) 6.1 67.5 (35.9–95.0)
1983–1987 41 16.6 (11.7–22.8) 13 6.2 (3.0–11.1) 14.2 63.5 (43.1–83.1)
1988–1992 42 13.4 (9.5–18.5) 11 4.8 (2.3–9.0) 20.6 59.1 (39.7–78.2)
1993–1997 65 16.3 (12.4–20.9) 13 3.3 (1.7–5.8) 23.2 86.6 (67.0–102.8)
1998–2002 84 18.6 (14.6–23.3) 29 6.0 (3.9–8.7) 35.3 44.5 (32.4–57.0)
*N: The effective number at risk in the fifth year of period survival analysisBMC Cancer 2008, 8:368 http://www.biomedcentral.com/1471-2407/8/368
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and 18.6 (Indians) respectively, while the highest and
lowest age-standardized mortality rates per 100,000 were
10.0 (Malays) and 6.0 (Indians) respectively. These rates
are still much lower than those found in the United States
(ASR: 118.4 and mortality rate: 21.7; per 100,000) and
the Nordic countries (e.g. Finland: ASR: 82.7 and mortal-
ity rate: 29.7, Sweden: ASR: 84.6 and mortality rate: 35.7;
per 100,000) for the same period [15,16]. One possible
risk factor for the increasing incidence in Singapore is the
adoption of a westernized diet that generally has a higher
intake of animal fats. The upward trend seen in the pros-
tate cancer incidence rates in Singaporean Chinese has
also been reported in other developed countries in Asia
such as Japan, China-Hong Kong and China-Shanghai
[17], whose affluence have also led to the adoption of
more westernized diets.
A few studies have reported that Asian diets may offer
some protection against prostate cancer [2,18,19]. For
example, legumes have been shown to confer protection
against prostate cancer in a recent multi-ethnic case-con-
trol study [20]. Singaporean Indians, especially those who
are vegetarians, generally consume more legumes than the
other two ethnic groups [21]. This may explain why the
incidence and mortality rates were lower in Singaporean
Indians compared to Singaporean Chinese. However, the
incidence of prostate cancer in Singaporean Indians was
higher compared to places in India such as Chennai (3.9
per 100,000) and Mumbai (6.9 per 100,000) for 1998 to
2002. This could be due to Singaporean Indians eating a
relatively more westernized diet than Indians from India.
Many studies have attempted to elucidate the nutritional
etiology of prostate cancer but definitive answers have not
been found. Hence, this would be an interesting and use-
ful avenue of research to pursue.
The ASRs for Singaporean Chinese were still increasing
during 1998 to 2002, in contrast to figures from the
United States where a peak was observed in the 1990s
[22]. One possible reason could be the slower uptake and
routine use of PSA testing in Singapore. In the United
States, 1.2% of white men received a PSA test in 1988 and
this increased to nearly 40% in 1994 [23]. There is no
comprehensive data to show the extent of PSA testing in
Singapore. However, from observation, the uptake of PSA
testing in Singapore is still low (Cheng 2007, personal
communication). PSA screening tests are offered to men
above 50 years of age as part of their general health screen-
ing, but this optional test comes with an additional cost.
This may explain why the trend in the age-adjusted pros-
tate cancer incidence rates from Singapore is similar to
that in the UK where the uptake of PSA is also slower than
in the United States [22]. The availability of transrectal
ultrasound and extended systematic and sextant biopsies
for prostate cancer detection in the late 1990s could have
also contributed towards sustaining the upward trend in
prostate incidence [17].
The strength of our study is the high quality data – using
DCO as a measure of completeness of reporting, the DCO
index was approximately 96% in the 1970s and close to
100% in the 1990s. The percentage of microscopic verifi-
cation was also high, ranging from 72.3% in 1968–1972
to 90.6% in 1998–2002 [1]. The limitation of using DCO
as a measure of the quality of the data is that we miss can-
cers that were diagnosed and unreported, but did not lead
to death within the study period. However, we expect only
very few incident cancers to be missed, as staff from the
cancer registry rigorously go through pathology reports
from both public and private laboratories to minimize
errors [1].
A limitation of a study like ours, where data is collected
over a time-span of more than 30 years, is that changing
diagnostic accuracy is unavoidable. Access to health care is
also likely to change over time, especially when a country
progresses economically, as was the case in Singapore.
These factors will not only affect prostate cancer but also
cancers at other sites. However, the different incidence
patterns reported for site-specific cancers in Singapore
over the last few decades [1] suggest that these factors
alone do not explain the steady increase in the incidence
of prostate cancer.
In conclusion, this study shows that the age-standardized
incidence rate of prostate cancer in Singapore has been
increasing, especially from the 1990s, and ethnic differ-
ences are apparent for incidence, mortality and survival
patterns. Possible explanations are lifestyle and dietary
factors, early detection or changes in treatment modalities
for prostate cancer.
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